Aegerion Pharmaceuticals Inc (AEGR)

Sector:
HEALTH CARE
Industry:
HEALTH CARE
SIC:
PHARMACEUTICAL PREPARATIONS
CEO:
Mary J. Szela
Employees:
318
ONE MAIN STREET, SUITE 800, CAMBRIDGE, MA 02142
(617) 500-7867

*** This stock is shown as delisted in our database. *** If you think this isn't correct then please let us know

Aegerion Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapies for patients with debilitating rare diseases in the United States.

Data derived from most recent annual or quarterly report
Market Cap 58.204 Million Shares Outstanding29.545 Million Avg 30-day Volume 335.467 Thousand
P/E Ratio0.0 Dividend Yield0.0 EPS-0.9
Price to Revenue0.533 Debt to Equity-19.4398 EBITDA-122.733 Million
Price to Book Value0.0 Operating Margin-88.45389999999999 Enterprise Value304.721 Million
Current Ratio1.017 EPS Growth-2.833 Quick Ratio0.339
1 Yr BETA 1.8002 52-week High/Low 0.0 / Profit Margin-106.6365
Operating Cash Flow Growth-272.7914 Altman Z-Score-2.7447 Free Cash Flow to Firm -3.803 Million
View SEC Filings from AEGR instead.

View recent insider trading info

Funds Holding AEGR (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding AEGR

Download CSV

Active Schedule 13D and 13G filings

Please sign in first

Recent Filings

Financial Reporting

Events (8k)

  • 8-K: filed on 2016-11-29:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 1.02: Termination of a Material Definitive Agreement
    Item 2.01: Completion of Acquisition or Disposition of Assets
    Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
    Item 3.03: Material Modifications to Rights of Security Holders
    Item 5.01: Changes in Control of Registrant
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2016-11-07:
    Item 5.07: Submission of Matters to a Vote of Security Holders
  • 8-K: filed on 2016-11-03:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2016-10-24:
    Item 8.01: Other Events
  • 8-K: filed on 2016-10-20:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 8.01: Other Events
  • 8-K: filed on 2016-10-03:
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2016-08-09:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2016-08-08:
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2016-07-20:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 2.05: Cost Associated with Exit or Disposal Activities
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2016-07-05:
    Item 5.07: Submission of Matters to a Vote of Security Holders
  • Proxy

    Prospectus

    All

    Open Market Buys/Sells Last 60 Days

    Open Market Buys (P)

    none

    Open Market Sells (S)

    none

    Exercise Derivative Conversion (M)

    none

    Current/Former Insiders

    Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

    GOTTO ANTONIO M JR MD D PHIL

    • Director
    No longer subject to file 2016-11-29 0

    THOMAS PAUL

    • Director
    No longer subject to file 2016-11-29 0

    VANLENT ANNE

    • Director
    No longer subject to file 2016-11-29 0

    PERRY GREGORY D

    • SEE REMARKS
    No longer subject to file 2016-11-29 0

    SMITH SANDFORD D

    • Director
    No longer subject to file 2016-11-29 0

    BARER SOL J

    • Director
    No longer subject to file 2016-11-29 0

    SCHEER DAVID

    • Director
    No longer subject to file 2016-11-29 0

    SZELA MARY T CHIEF EXECUTIVE OFFICER

    • Officer
    • Director
    No longer subject to file 2016-11-29 0

    BROADFIN HEALTHCARE MASTER FUND LTD

    BROADFIN CAPITAL, LLC

    KOTLER KEVIN

    • 10% Owner
    No longer subject to file 2016-11-29 0

    PLUTZKY JORGE MD

    • Director
    No longer subject to file 2016-11-29 0

    STERN DONALD K

    • Director
    No longer subject to file 2016-11-29 0

    HARSHBARGER BENJAMIN GENERAL COUNSEL AND SECRETARY

    • Officer
    No longer subject to file 2016-11-29 0

    LOUIS ROGER CHIEF COMPLIANCE OFFICER

    • Officer
    No longer subject to file 2016-11-29 0

    CHAN BARBARA Y VP, CHIEF ACCOUNTING OFFICER

    • Officer
    No longer subject to file 2016-11-29 0

    BUONO LINDA SR. VP, HUMAN RESOURCES

    • Officer
    No longer subject to file 2016-11-29 0

    ORLOFF JOHN J EVP, RESEARCH AND DEVELOPMENT

    • Officer
    0 2016-11-01 0

    MENES REMI A GLOBAL CHIEF COMMERCIAL OFF.

    • Officer
    0 2016-09-12 0

    QLT INC/BC

    • 10% Owner
    0 2016-06-14 0

    CARTER MARTHA J. SEE REMARKS

    • Officer
    0 2016-05-09 0

    CURTIS ERIC PRESIDENT, U.S. COMMERCIAL

    • Officer
    0 2015-08-26 0

    COOK ANNE MARIE SVP, GENERAL COUNSEL

    • Officer
    0 2015-08-04 0

    SUMERAY MARK CHIEF MEDICAL OFFICER

    • Officer
    0 2015-08-04 0

    ANDREWS WILLIAM T. SEE REMARKS

    • Officer
    0 2015-08-04 0

    WEGER MARY CHIEF PERFORMANCE OFFICER

    • Officer
    0 2015-08-04 0

    AUBUCHON DAVID CHIEF FINANCIAL OFFICER

    • Officer
    0 2015-06-05 0

    BEER MARC D CHIEF EXECUTIVE OFFICER

    • Officer
    • Director
    0 2015-04-01 0

    FITZPATRICK MARK J. CHIEF FINANCIAL OFFICER

    • Officer
    0 2015-04-01 0

    FRASER CRAIG CHIEF OPERATING OFFICER

    • Officer
    0 2015-04-01 0

    PERCEPTIVE ADVISORS LLC

    EDELMAN JOSEPH

    PERCEPTIVE LIFE SCIENCES MASTER FUND LTD

    • 10% Owner
    No longer subject to file 2013-06-15 0

    ALTA BIOPHARMA PARTNERS III LP

    PENHOET EDWARD

    CHAMPSI FARAH

    HURWITZ EDWARD

    ALTA BIOPHARMA MANAGEMENT III LLC

    ALTA BIOPHARMA PARTNERS III GMBH & CO BETEILIGUNGS KG

    ALTA EMBARCADERO BIOPHARMA PARTNERS III LLC

    KILEY ALISON

    • 10% Owner
    No longer subject to file 2012-10-15 0

    ROTHERA MARK GLOBAL PRESIDENT

    • Officer
    0 2012-05-01 0

    ADVENT INTERNATIONAL CORP/MA

    • MEMBER OF GROUP > 10%
    2,457,879 2012-03-09 0

    ADVENT INTERNATIONAL LLC

    • MEMBER OF GROUP > 10%
    2,430,765 2012-03-09 0

    AHLS III GP LIMITED PARTNERSHIP

    • MEMBER OF GROUP > 10%
    2,430,765 2012-03-09 0

    ADVENT HEALTHCARE & LIFE SCIENCES III LIMITED PARTNERSHIP

    • MEMBER OF GROUP > 10%
    985,052 2012-03-09 0

    ADVENT PARTNERS HLS III LIMITED PARTNERSHIP

    • MEMBER OF GROUP > 10%
    27,114 2012-03-09 0

    ADVENT HEALTHCARE & LIFE SCIENCES III-A LIMITED PARTNERSHIP

    • MEMBER OF GROUP > 10%
    1,445,713 2012-03-09 0

    INDEX VENTURE ASSOCIATES III LTD

    INDEX VENTURES III (DELAWARE) L.P.

    INDEX VENTURES III (JERSEY) L.P.

    INDEX VENTURES III PARALLEL ENTREPRENEUR FUND (JERSEY) L.P.

    YUCCA PARTNERS L.P. JERSEY BRANCH

    • 10% Owner
    No longer subject to file 2012-01-30 0

    ALTA BIOPHARMA PARTNERS III LP

    PENHOET EDWARD

    CHAMPSI FARAH

    HURWITZ EDWARD

    ALTA BIOPHARMA MANAGEMENT III LLC

    ALTA BIOPHARMA PARTNERS III GMBH & CO BETEILIGUNGS KG

    ALTA EMBARCADERO BIOPHARMA PARTNERS III LLC

    • 10% Owner
    8,055,553 2011-08-08 0

    KILEY ALISON

    • Director
    • 10% Owner
    2,690,251 2011-08-08 0

    OLLIER MICHELE

    • Director
    • 10% Owner
    2,131,827 2011-07-29 0

    TRIBBLE DIANE L. CHIEF SCIENTIFIC OFFICER

    • Officer
    0 2011-03-01 0

    FISHERMAN JASON S

    • Director
    7,861 2010-10-27 0

    ALTA BIOPHARMA PARTNERS III LP

    ALTA BIOPHARMA MANAGEMENT III LLC

    ALTA BIOPHARMA PARTNERS III GMBH & CO BETEILIGUNGS KG

    ALTA EMBARCADERO BIOPHARMA PARTNERS III LLC

    DELEAGE JEAN

    CHAMPSI FARAH

    PENHOET EDWARD

    HURWITZ EDWARD

    • 10% Owner
    2,680,551 2010-10-27 0

    LEWIS WILLIAM PRESIDENT, PFO AND TREASURER

    • Officer
    412,761 2010-10-27 0

    PELLIZZARI CHRISTINE A EVP, GEN. COUNSEL & SECRETARY

    • Officer
    0 2010-10-21 0

    SCHEER INVESTMENT HOLDINGS VII LLC

    • DIRECTOR IS MANAGING MEMBER
    640,154 2010-10-21 0

    CAVAN JOHN T VP & CHIEF ACCOUNTING OFFICER

    • Officer
    0 2010-10-21 0

    Insider Transactions Last 60 Days

    Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
    Disposed
    Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days
    No current insider transactions

    * -

    Transaction Code Definitions
    Code Definition
    A Grant, award or other acquisition pursuant to Rule 16b-3(d)
    C Conversion of derivative security
    D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
    E Expiration of short derivative position
    F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
    G Bona fide gift
    H Expiration (or cancellation) of long derivative position with value received
    I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
    J Other acquisition or disposition
    L Small acquisition under Rule 16a-6
    M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
    O Exercise of out-of-the-money derivative security
    P Open market or private purchase of non-derivative or derivative security
    S Open market or private sale of non-derivative or derivative security
    U Disposition pursuant to a tender of shares in a change of control transaction
    W Acquisition or disposition by will or the laws of descent and distribution
    X Exercise of in-the-money or at-the-money derivative security
    Z Deposit into or withdrawal from voting trust

    IBR Securities Loan Availability

    Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

    Security Date/Time Rebate Rate Fee Rate Shares Available

    Current Active Short Positions

    Holder Issuer Net Short Position Position Date Origin

    No recent transactions

    *** To see all congressional transactions (since 2022) for this stock, please use the congressional transaction search page***

    Elevate your investments